<div>A recent tour-de-force study by the US researchers describes a comprehensive approach to completely map mutations to the SARS-CoV-2 receptor-binding domain (RBD) that escape antibody binding &ndash; enabling, in turn, rational design of antibody therapeutics and appraisal of the antigenic consequences of viral evolution. The results are currently available in a bioRxiv preprint paper.</div>